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ABSTRACT
Declining incidence of oropharyngeal candidosis and opportunistic infections over recent years can be
attributed to the use of highly active anti-retroviral therapy (HAART). Infection with C. albicans generally
involves adherence and colonization of superficial tissues. During this process, budding yeasts are able to
transform to hyphae and penetrate into the deep tissue. Using the biocell tracer system, C. albicans hyphal
growth was dynamically observed at the cellular level. Ritonavir was effective in the inhibition of hyphal
growth with growth rate of 0.8 μm/min. This study showed the in vitro effect of HIV anti-retroviral drug on the
growth rate of the C. albicans hyphae.
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INTRODUCTION
Oropharyngeal candidosis is a frequent opportunistic mycosis
in immunocompromised patients. The main causative agent of
this infection is Candida albicans (30). C. albicans is a dimorphic
fungus with ability to transform between yeast and hyphal cells.
Both forms are invariably present in lesions. Evidence suggests
that the mycelial form is important in the pathogenesis of
candidoses (30). Putative virulence factors of C. albicans include
cell wall adhesion, phenotypic switching, hyphal formation,
thigmotropism and secretion of proteases and others hydrolytic
enzyme (36). Production of extracellular proteases in Candida
was first reported by Staib, 1969 (22,33). C. albicans has the
ability to secrete proteases facilitating the invasion of mucosal
tissue (13). Declining incidence of oropharyngeal candidoses
and opportunistic infections over recent years can be attributed
to the use of highly active anti-retroviral therapy (HAART),
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including HIV protease inhibitor (PI), in the treatment of HIV-
infected patient (8,19,26). This has been attributed to Candida
proteases belonging the same protease class as HIV protease.
Recent studies suggest a correlation exist between high
protease secretion and reduced susceptibility to some azoles
by C. albicans isolates from HIV-infected patients before
HAART (4,11,25,31,37). Kretschmar et al., 1999 (22)
demonstrated that both germ tubes and protease activity
correlated with tissue damage in C. albicans infection. However
little is known about the effect of HIV protease inhibitor on
Candida hyphal growth. The main treatment of Candida
infections has been based on azole and polyene therapy (20).
Azoles have also been showed to interfere with respiration
process, inhibition of the hyphal formation and activity of
membrane-bound enzymes (7,23). This study investigated the
effect of an HIV protease inhibitor on the growth rate of Candida
single hyphal by a Bio-Cell Tracer system.
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MATERIALS AND METHODS
Yeasts: Candida albicans ATCC 90028 reference strain
Material
Amphotericin B (AMB) (Bristol-Myers Squibb, UK), reagent
grade was dissolved in dimethyl sulfoxide solvent (DMSO).
Ritonavir (RT) (Abbott Co., USA) was dissolved in methanol.
Other chemicals used included poly-L-lysine (Sigma Chemical
Co., Ltda., St. Louis, Mo., USA), fetal calf serum 5% (GIBCO,
Laboratories, USA), and RPMI-1640 medium (Nissui
Pharmaceutical Co., Japan) which was buffered with
morpholinepropanesulfonic acid (MOPS; Sigma Chemical
Co., USA).
Antifungal susceptibility test
To determine the MIC of the strain, antifungal susceptibility
tests were performed as previously described by the National
Committee for Clinical Laboratory Standards (NCCLS, 1997) (28).
Cellular yeast growth
Ritonavir and amphotericin B were tested at concentration
ranging from 0.125 to 64 μg/mL. Single colonies of C. albicans
ATCC 90028 strain was inoculated into 10-mL aliquots of YNB
(yeast nitrogen broth, Difco, USA) medium containing 2%
glucose (Difco, USA). These were incubated at 30ºC for 24 h
with shaking at 250 rpm. Cells were harvested by centrifugation
at 3500 rpm for 5 min, at 4ºC, washed twice with YNB medium
and resuspend in 10 ML of YNB medium. Cells densities were
adjusted spectrophotometrically to an optical density (OD600)
with value of 0.42 at 600 nm and then diluted to a final
concentration of 2 x 103 cells/mL in YNB medium containing 2%
glucose. Preparation of antifungal drugs and dilution schemes
were performed in accordance with the National Committee for
Clinical Laboratory Standards (NCCLS, 1997). Specific growth
rates (cells.h-1) of the strain were determined in aerobic batch
cultures at 37ºC, 48 h using a Bioscreen C Analyser (Oy Growth
curves AB Ltda., Helsinki, Finland) (16).
Monitoring of single hyphal growth by the Bio-Cell Tracer
system
Cells were pre-cultured in RPMI-1640 medium at 37ºC with
shaking at 150 rpm for 24h. Cells were washed 3 times with
saline solution by centrifugation at 2000 rpm and cell count
adjusted to approximately 1 x 106 cells/mL. Plastic tissue culture
dishes (35 x 10 mm, Nunc, Denmark) were used as culture vessels.
The inner surface of this vessel was covered with 0.01% poly-
L-lysine. Cells suspension (1 mL) was inoculated onto the culture
vessel and kept for 1 hour at room temperature. Using this
procedure, cells not adhered to the poly-L-lysine on culture
dishes were removed and 1 mL RPMI 1640 supplemented with
5% fetal calf serum was added. The culture vessel was set on
the microscope chamber stage at 35ºC to get up to 90% hyphal
growth. Fifteen to twenty hyphal tips were selected and
monitored by the Bio-Cell Tracer system (BCT, Hidan Co., Ltd,
Chiba Japan). This automatic system consists of a microscope
(Olympus; IMT-2) and a digital image analyser (Flovel, Hidan
Co., Ltd, Chiba Japan) using a computer program that traces
individual hyphal tips. The analytical precision was 0.01
μm.min-1. The apparatus can trace growing hyphal tips at speeds
in the range of 0.5 to 20 μm.min-1. Growth rates of hyphal tips
were measured for 10 min intervals. After stable growth,
approximately 1 hour, the medium from the culture vessel was
removed and fresh RPMI medium containing the drug to be
tested was added or control no drug added. The drugs were
tested in separate sets in which AMB was used at concentration
of ¼ MIC, 0.0125 μg/mL, and Ritonavir at concentration of 58
μg/mL. The growth rate was monitored for 2-4 h.
RESULTS AND DISCUSSION
Protease inhibitors (PI) caused a revolution in treating HIV
infection when they were introduced in 1996. The introduction
of highly active antiretroviral therapy (HAART) including PI
has been accompanied by a reduction in the frequency of
many of the secondary infections caused by HIV infection,
including oral lesions (2,8-10,12,19). Infection by C. albicans
generally involves adherence and colonization of superficial
tissues (13,22,24). During this process, budding yeast cells
are able to transform to hyphae and penetrate into the deep
tissue (29).
In the present study the antifungal susceptibility tests for
the ATCC 90028 strain gave a MIC to AMB of 1 μg/mL. The
effect of the drugs on the yeast form growth rate (cells.h-1) of
the ATCC 90028 strain was determined in aerobic batch cultures
using a Bioscreen C Analyser. Ritonavir and amphotericin B
were tested at concentration ranging from 0.125 to 64 μg/mL.
AMB inhibited 80% of growth at a concentration of 1 μg/mL
and was fungicidal at a concentration >1 μg/mL. In contrast
Ritonavir showed a progressive inhibitory effect on the yeast
growth rate at higher concentrations, inhibiting 85% of the cell
growth at concentrations of 0.25 μg/mL. However, at
concentrations of 64 μg/mL, Ritonavir was not fungicide.
Ritonavir shows mean maximum concentrations in serum
(Cmaxs) of 0.058 mg/mL after oral administration doses of 100
mg/day. Using the BCT system, cell culture after 1h showed up
to 90% hyphal growth then the hyphal tips were exposured to
58 μg/mL of ritonavir (Fig.1). Figs. 2 and 3 show the time
measurement in minutes and the growth rate (μm.min-1) of single
hyphae. In the post-exposure period the hyphal growth rate in
the presence of Ritonavir was 0.8 ± 0.33 μm/min. In contrast
AMB at a sub inhibitory concentration (0.125 μg/mL) caused
only a slight reduction in hyphal growth (Fig. 3) with a growth
rate of 2.8 ± 0.6 μm/min. The mean growth rate of the untreated
hyphae was constant at approximately 2.5 μm/min at 37ºC.
Anti-retroviral drug effect on C. abicans
227
Therefore the hyphal growth was progressively reduced after
the Ritonavir had been added, indicating hyphal sensitivity to
Ritonavir. Several antifungal susceptibility tests such as
microdilution (NCCLS), agar diffusion (17) and flow cytometry
are designed to work primarily with yeasts and yeast-like fungi.
However, for filamentous fungi or hyphal invasion, these
standard antifungal susceptibility tests do not accurately
determine the effectiveness of a drug as an antifungal agent.
The main treatment of Candida infections has been based on
azole and polyene therapy (20). Although amphotericin B shows
high toxicity, it is still the drug of choice for systemic mycosis
(14). Amphotericin B act at the level of ergosterol by binding to
this molecule. Azoles such as fluconazole, itraconazole or
voriconazole inhibit the cytochrome P450 responsible for the
14α demethylation of lanosterol (CYP51) and thus block
ersgosterol biosynthesis (21). Inhibition of ergosterol
biosynthesis in C. albicans causes a variety of functional
alterations in the cell membrane such as permeability changes,
leakiness and disruptive interactions with non-sterol and lipid
components. Ergosterol biosynthesis is more sensitive to
azoles in mycelial cultures than yeast cultures, and this
observation has been used to justify the efficacy of azoles in
vivo (13,18,35).
Recent studies in vitro suggest that HIV- protease inhibitors
cause inhibition of growth with Pneumocystis carinii (2),
Candida albicans (8), and Toxoplasma gondii (12). Indinavir
caused an insignificant inhibitory effect in line with that of AZT
and Saquinavir was only lethal to Toxoplasma at concentrations
cytotoxic to the human host cells. Nelfinavir and Ritonavir,
however, blocked parasite growth at concentrations that were
sub-lethal to human host cells. The main mechanism of
pathogenicity in Candida infection is by hyphal growth (15,18).
The major treatment of Candida infections has been the use of
azole and polyene drugs (20) which inhibit hyphal growth and
therefore prevent candidosis development. The effect of HIV
protease inhibitors on Candida hyphal growth is unclear.
In studies using scanning and transmission electron
microscopy, some antifungal drugs caused inhibition of
growth and morphological changes in Candida albicans and
Aspergillus fumigatus (1,3,34). These structural alterations
were attributed to depletion of ergosterol (32). Hyphal-deficient
Figure 1. Photomicrographs of dynamic hyphal tip growth, (a)
main screen showing full germination and (b) the tracing process
of hyphal tip growth.
Figure 2. Time course of the growth rate of individual hyphae
of C. albicans. Ritonavir at concentration of 58 μg/mL was
added after 60 min of stable growth rate of hyphal tip.
Figure 3. Time course of the growth rate of individual hyphae
of C. albicans. AMB at concentration of 0.125 μg/mL was added
as indicated by the arrow.
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mutants are known to be avirulent in infections (13,24). C.
albicans extracellular proteolytic activity due to secreted
aspartic proteases has been purposed as putative virulence
factor during the tissue invasion process by hyphal cells. Felk
et al., 2002 (4) showed that strains that produced hyphal cells
but lacked hyphal-associated proteases were less invasive.
Thus the hyphal morphology per si seems not make the fungus
invasive (13). Several studies (5,6,8,27) showed inhibitory
effects of Indinavir and Ritonavir on the yeast growth of
Candida albicans. They established that a particularly
virulent form of C. albicans associated with HIV infection
produces a secretory aspartyl protease. This protease is
inhibited by the HIV protease inhibitors. Using an experimental
mouse model of vaginal candidosis, De Bernardis et al., 1999
(8) demonstrated that the PIs had a therapeutic efficacy
comparable to that of fluconazole.
The present study was succeeded in showing the inhibitory
effect of ritonavir on a single hyphae tip growth of C. albicans.
Our findings suggest that ritonavir was effective in the
inhibition of hyphal growth therefore explaining in part the
reduction of oral candidoses prevalence. The mechanism of PI
action in controlling virulence factors associated with hyphal
formation and growth is not known and requires further
investigations.
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RESUMO
Efeito da droga anti-retroviral HIV-1 no crescimento
de hifas de C. albicans monitoradas pelo sistema
“Bio-Cell Tracer”
O declínio na incidência de candidose orofaríngea e infecções
oportunistas associadas a infecção pelo HIV tem sido atribuído a
introdução da terapia antiretroviral combinada (HAART). Infecção
por C. albicans envolve aderência e colonização da mucosa
superficial. Durante este processo leveduras são capazes de
transformar-se na forma de hifas e penetrar nos tecidos mais
profundos. Usando o sistema “Bio-Cell Tracer”, o crescimento
de hifas de C. albicans foi observado dinamicamente a nível
celular. Ritonavir, inibidor de protease do HIV, foi efetivo na
inibição do crescimento de hifas com media de 0.8 μm/min.O
presente estudo demonstrou o efeito in vitro de um agente anti-
retroviral HIV sobre o crescimento de hifas de C. albicans.
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